Actavis plc and Durata Therapeutics, Inc. announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) with respect to Actavis’ pending acquisition of Durata.The early termination of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in the fourth quarter of 2014.
Date: November 3, 2014
Source: Actavis
Filed Under: Drug Discovery
